演讲嘉宾--于强

于强
yuq@gis.a-star.edu.sg
https://www.a-star.edu.sg/gis/our-people/investigator-details.aspx?source=faculty_member&user_id=41
新加坡基因组研究院,资深研究室主任,教授 新加坡国立大学医学院,教授(兼职) 杜克-新加坡国立大学医学院,教授(兼职)
研究学习经历:

Dr. Qiang Yu is currently a Senior Group Leader and Professor of Cancer Therapeutics and Stratified Oncology Program at the Genome institute of Singapore (GIS). He also has adjunct professorship appointments at Yong Loo Lin School of Medicine of National University of Singapore and DUKE-NUS medical school. He obtained his medical training in China (Qingdao University Medical School and Peking Union Medical College) and got his Ph.D from Queen’s University in Canada. After his postdoctoral training at National Cancer Institute of NIH, he joined GIS in 2002 as a Principal Investigator till now. His lab has been studying genetic and epigenetic mechanisms that allow cancer cells to escape apoptotic cell death in response to treatments. In recent years, his lab is more focused on translational cancer research with the aim at developing new therapeutic strategies as well as diagnostic solutions. His lab is located at the Genome Institute of Singapore, where he uses integrative approaches including genomics and large scale functional analysis to conduct both basic and translational research.

近期发表论文:
  1. Sylvia Mahara, Puay Leng Lee, Min Feng, Vinay Tergaonkar, Wee Joo Chng, and Qiang Yu. Hypoxia inducible factor 1-alpha activation underlies a functional switch of paradoxical role of EZH2/PRC2 in breast cancer. Proc Natl Acad Sci U S A. 2016 Jun 28; 113(26)Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Qiang YU "IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel." Nat Communication. 2015; 6: 8746
  2. Feng M, Bao Y, Li Z, Li J, Gong M, Lam S, Wang J, Marzese DM, Donovan N, Tan EY, Hoon DS, Qiang Yu. "RASAL2 activates RAC1 to promote triple-negative breast cancer progression." J Clinical Investigation, 2014, 124(12):5291-304
  3. Tan J, Li Z, Lee PL, Guan P, Aau M, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Qiang Yu. "PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy." Cancer Discovery.  2013, 3(10):1156-71
  4. Shuet Theng Lee1, Min Feng, Yong Wei, Zhimei Li, Yuanyuan Qiao1, Peiyong Guan, Meiyee Aau, Xia Jiang, Chew Hooi Wong, Kelly Huynh, Jinhua Wang, Juntao Li, K. Murthy Karuturi, Ern Yu Tan, Dave SB Hoon, Yibin Kang, Qiang Yu. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. Proc Natl Acad Sci U S A, 2013 Jul 2;110(27):11121-6
  5. Shuet Theng Lee, Zhimei Li, Zhenlong Wu, Meiyee Aau, Peiyong Guan, R.K. Murthy Karuturi, Yih Cherng Liou and Qiang Yu ."Context-Specific Regulation of NF-kB Target Gene Expression by EZH2 in Breast Cancers". Molecular Cell 43, 798–810, 2011.
  6. Jing Tan, Puay Leng Lee, Zhimei Li, Xia Jiang, Yaw Chyn Lim, Shing Chuan Hooi and Qiang Yu. B55β-associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 18:459-471, 2010
  7. Xiaojing Yang, Min Feng, Xia Jiang, Zhenlong Wu, Meiyee AAu, Zhimei Li, and Qiang Yu. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes & Development. 2009 23: 2388-2393.
会议报告摘要:
New approaches to target and monitor breast cancer progression and therapeutic resistance(4月23日 ,10:30-11:00am)

Clinical management of aggressive breast cancer remains a challenge due to high risk of tumor recurrence and distant metastasis. Although chemotherapy may be effective initially, a subset of patients often progress aggressively due to acquired chemoresistance, resulting in metastatic relapse. Despite being a major cause of mortality, treatment options for advanced disease remains limited, necessitating identification of new therapeutic strategies that target metastatic recurrence and chemoresistance. Our research has been focused on the fundamental biology questions related to the above clinical problems and wish to identify new treatment strategies that may lead to improved patient survival. Towards this goal, we have identified a number of potential actionable targets which can be exploited to target breast cancer metastasis and drug resistance. In addition, we are also interested in developing diagnostic test which can be used to predict and monitor the disease progression. To this end, we have identified a genetic marker associated with tumor initiating cells and translated this finding into a liquid biopsy test. Through intensive collaborations with both local and overseas clinicians, we are able to show that the blood-based cell-free DNA test we have developed is robust in identifying breast cancer patients at high risk for recurrence and also has the potential for post-treatment surveillance.

网站首页 | 会议简介 | 演讲嘉宾 | 大会日程 | 会议注册 | 交通/住宿 | 联系我们 |

第四届肿瘤基础和转化医学前沿国际研讨会